[go: up one dir, main page]

WO2006066183A3 - Novel saframycin analogs as therapeutic agents - Google Patents

Novel saframycin analogs as therapeutic agents Download PDF

Info

Publication number
WO2006066183A3
WO2006066183A3 PCT/US2005/045880 US2005045880W WO2006066183A3 WO 2006066183 A3 WO2006066183 A3 WO 2006066183A3 US 2005045880 W US2005045880 W US 2005045880W WO 2006066183 A3 WO2006066183 A3 WO 2006066183A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
saframycin
novel
therapeutic agents
saframcyin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/045880
Other languages
French (fr)
Other versions
WO2006066183A2 (en
Inventor
Joseph H Saugier
Martin Sendzik
Jeffrey R Spencer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Axys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals Inc filed Critical Axys Pharmaceuticals Inc
Publication of WO2006066183A2 publication Critical patent/WO2006066183A2/en
Publication of WO2006066183A3 publication Critical patent/WO2006066183A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to saframcyin analogs that are useful in the treatment of cancer. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
PCT/US2005/045880 2004-12-16 2005-12-16 Novel saframycin analogs as therapeutic agents Ceased WO2006066183A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63713904P 2004-12-16 2004-12-16
US60/637,139 2004-12-16

Publications (2)

Publication Number Publication Date
WO2006066183A2 WO2006066183A2 (en) 2006-06-22
WO2006066183A3 true WO2006066183A3 (en) 2006-08-03

Family

ID=36337415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/045880 Ceased WO2006066183A2 (en) 2004-12-16 2005-12-16 Novel saframycin analogs as therapeutic agents

Country Status (1)

Country Link
WO (1) WO2006066183A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50510B (en) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal FORMULATIONS CONTAINING ECTEINASCIDINE AND DISAHARID
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JOP20190254A1 (en) 2017-04-27 2019-10-27 Pharma Mar Sa Antitumoral compounds
US10526334B2 (en) 2017-07-19 2020-01-07 California Institute Of Technology Methods for preparing bis-tetrahydroisoquinoline-containing compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040477A2 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040477A2 (en) * 2000-11-03 2002-05-23 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
US20040204419A1 (en) * 2000-11-03 2004-10-14 Myers Andrew G. Saframycins, analogues and uses thereof
WO2005118584A2 (en) * 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer

Also Published As

Publication number Publication date
WO2006066183A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
MY177111A (en) Substituted amide derivatives and methods of use
NO20063787L (en) Therapeutic preparations
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
GB2430935A (en) Tetrapeptide analogs
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
IL187438A0 (en) Pyrrolopyridine derivatives and pharmaceutical compositions containing the same
WO2002014311A3 (en) Urea compounds and methods of uses
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
TNSN07322A1 (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2006058868A8 (en) Substituted pteridines for treating inflammatory diseases
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
WO2007064932A3 (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
MX2009009466A (en) Tricyclic compounds useful in treating iron disorders.
WO2006138528A3 (en) Tricyclic opioid modulators
WO2006069276A3 (en) TRICYCLIC ō-OPIOID MODULATORS
WO2005055939A3 (en) Vinca derivatives
TW200628473A (en) Novel heterocycles
WO2005103010A3 (en) Pyrazole derivatives useful for the treatment of cancer
WO2005118584A3 (en) Saframycin analogs as therapeutic agents in the treatment of cancer
WO2008033930A3 (en) Vinca derivatives
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 05854562

Country of ref document: EP

Kind code of ref document: A2